{"id":61572,"date":"2025-07-14T04:05:18","date_gmt":"2025-07-14T02:05:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/"},"modified":"2025-07-14T04:05:18","modified_gmt":"2025-07-14T02:05:18","slug":"golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/","title":{"rendered":"Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China"},"content":{"rendered":"
\n

SHANGHAI–(BUSINESS WIRE)–Golden Age Health Pte. Ltd. (\u201cGAH<\/b>\u201d) and Innostellar Biotherapeutics Co., Ltd.<\/b> (\u201cInnostellar<\/b>\u201d) today announced an exclusive ten-year Promotion Services Agreement<\/b> that grants GAH sole rights to commercialise and promote Innostellar\u2019s first-in-class gene-therapy candidate LX-101<\/b> across Mainland China. Leveraging its full-spectrum patient-focused launch platform covering disease and medical education, market access and patient support to address the unmet needs along the patient journey such as disease awareness, timely diagnosis and treatment, treatment accessibility and affordability. GAH, along with Innostellar will act with urgency to bring this life-changing therapy to patients affected by inherited retinal dystrophies due to RPE 65 gene mutation in Mainland China so they can \u201csee the future, clearly\u201d.<\/i><\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cPartnering with Innostellar positions GAH at the forefront of gene therapy in China\u2019s rapidly expanding ophthalmology market,\u201d said Francis Wan, Chief Executive Officer of Golden Age Health<\/b>. \u201cOur integrated approach aims to deliver sight-saving innovation to patients swiftly and comprehensively.\u201d<\/p>\n

\nDr Wang Fenghua, Founder & CEO of Innostellar<\/b>, added: \u201cBy joining forces with GAH, we can ensure LX-101 reaches patients across China rapidly and\u2014crucially\u2014at prices families can afford, thanks to efficiencies gained through local development and manufacturing. Improving patient access lies at the heart of our mission.<\/p>\n

\nAbout Inherited Retinal Dystrophies<\/b><\/p>\n

\nInherited retinal dystrophies (IRDs)\u2014including retinitis pigmentosa (RP)<\/b>\u2014are genetic disorders that progressively destroy photoreceptors, leading to severe vision impairment or blindness, often from childhood. RP affects approximately 1 in 3,000\u20134,000 people worldwide<\/b> and is officially listed in China\u2019s National Rare Disease Catalog<\/b> (first list, 2018), underscoring the country\u2019s commitment to improving outcomes for affected patients.<\/p>\n

\nAbout LX-101<\/b><\/p>\n

\nLX-101 is an adeno-associated-virus (AAV) gene therapy delivering a functional RPE65<\/b> gene directly to retinal cells, aiming to restore the visual cycle in patients with biallelic RPE65-mutation IRDs. The programme is in Phase III clinical development in China<\/b>, with top-line results expected in Q4 2025<\/b> and initiate NMPA New Drug Application soon after. If approved, LX-101 would provide eligible patients with a single-dose, durable treatment designed to halt\u2014or potentially reverse\u2014vision loss.<\/p>\n

\nAbout Golden Age Health<\/b><\/p>\n

\nGolden Age Health is a specialty pharmaceutical company dedicated to redefining patient access to medicine across China, Asia-Pacific and beyond. Headquartered in Singapore, GAH pairs data-driven market-access expertise with deep medical-affairs and RWE capabilities to bring high-impact therapies to underserved populations.<\/p>\n

\nAbout Innostellar Biotherapeutics<\/b><\/p>\n

\nInnostellar Biotherapeutics is a Shanghai-based biotechnology firm advancing innovative gene-therapy medicines for ocular and other genetic diseases and chronic diseases. Its pipeline is led by LX-101, the first gene therapy of its kind to enter late-stage development in China.<\/p>\n

\nForward-Looking Statements<\/i><\/p>\n

\nThis release contains forward-looking statements, including expectations regarding clinical development, regulatory approvals and commercial launches. These statements involve risks and uncertainties that may cause actual outcomes to differ materially.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia & Investor Contacts<\/b><\/p>\n

\nG<\/b>olden Age Health<\/b>
https:\/\/www.gahbioventures.com\/<\/a>
Media\/IR:<\/b> info@gahbioventures.com<\/a><\/p>\n

\nInnostellar Biotherapeutics<\/b>
https:\/\/www.innostellarbio.cn\/<\/a>
Media\/IR:<\/b> ir@innostellar.cn<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SHANGHAI–(BUSINESS WIRE)–Golden Age Health Pte. Ltd. (\u201cGAH\u201d) and Innostellar Biotherapeutics Co., Ltd. (\u201cInnostellar\u201d) today announced an exclusive ten-year Promotion Services Agreement that grants GAH sole rights to commercialise and promote Innostellar\u2019s first-in-class gene-therapy candidate LX-101 across Mainland China. Leveraging its full-spectrum patient-focused launch platform covering disease and medical education, market access and patient support to … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61572","6":"format-standard","7":"category-industry"},"yoast_head":"\nGolden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI–(BUSINESS WIRE)–Golden Age Health Pte. Ltd. (\u201cGAH\u201d) and Innostellar Biotherapeutics Co., Ltd. (\u201cInnostellar\u201d) today announced an exclusive ten-year Promotion Services Agreement that grants GAH sole rights to commercialise and promote Innostellar\u2019s first-in-class gene-therapy candidate LX-101 across Mainland China. Leveraging its full-spectrum patient-focused launch platform covering disease and medical education, market access and patient support to ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-14T02:05:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250714880327\/en\/2517956\/22\/Logo_with_text_JPG.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China\",\"datePublished\":\"2025-07-14T02:05:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\\\/\"},\"wordCount\":511,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250714880327\\\/en\\\/2517956\\\/22\\\/Logo_with_text_JPG.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\\\/\",\"name\":\"Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250714880327\\\/en\\\/2517956\\\/22\\\/Logo_with_text_JPG.jpg\",\"datePublished\":\"2025-07-14T02:05:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250714880327\\\/en\\\/2517956\\\/22\\\/Logo_with_text_JPG.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250714880327\\\/en\\\/2517956\\\/22\\\/Logo_with_text_JPG.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/","og_locale":"en_US","og_type":"article","og_title":"Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China - Pharma Trend","og_description":"SHANGHAI–(BUSINESS WIRE)–Golden Age Health Pte. Ltd. (\u201cGAH\u201d) and Innostellar Biotherapeutics Co., Ltd. (\u201cInnostellar\u201d) today announced an exclusive ten-year Promotion Services Agreement that grants GAH sole rights to commercialise and promote Innostellar\u2019s first-in-class gene-therapy candidate LX-101 across Mainland China. Leveraging its full-spectrum patient-focused launch platform covering disease and medical education, market access and patient support to ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/","og_site_name":"Pharma Trend","article_published_time":"2025-07-14T02:05:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250714880327\/en\/2517956\/22\/Logo_with_text_JPG.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China","datePublished":"2025-07-14T02:05:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/"},"wordCount":511,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250714880327\/en\/2517956\/22\/Logo_with_text_JPG.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/","url":"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/","name":"Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250714880327\/en\/2517956\/22\/Logo_with_text_JPG.jpg","datePublished":"2025-07-14T02:05:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250714880327\/en\/2517956\/22\/Logo_with_text_JPG.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250714880327\/en\/2517956\/22\/Logo_with_text_JPG.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/golden-age-health-and-innostellar-biotherapeutics-sign-exclusive-10-year-collaboration-to-accelerate-lx-101-gene-therapy-for-inherited-retinal-dystrophies-due-to-rpe-65-gene-mutation-in-mainland-china\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61572"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61572\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}